“The Novartis-Aetna-Cigna deal has a lot of pressure and I think that ultimately the price of medicine will come down and be more reasonable based on this, as we explore how a free market based in rational healthcare consumption can improve lifespan and health.”
“Pharma has been looking at ways to reduce pricing such as value-based pricing, indication-based pricing, and quality of year in life pricing,” Bithoney described new payment models for the pharmaceutical industry.
ليست هناك تعليقات:
إرسال تعليق